Criteria
| Eligible Active Ingredient: | Ketotifen Tablet. As an oral solid preparation not exceeding 2mg |
| With Effective From: | 1-Jun-17 |
| Indication Permitted: | Indications: Symptomatic treatment of allergic rhinitis and chronic urticaria |
| Maximum Daily Dose: | 2mg |
| Maximum Supply per Transaction: | 10 days |
| Minimum Age of User: | 3 years |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Ketotifen Tablet
Ketotifen is a relatively selective, non-competitive histamine antagonist (H1-receptor) and mast cell stabilizer. Ketotifen inhibits the release of mediators from mast cells involved in hypersensitivity reactions. Decreased chemotaxis and activation of eosinophils have also been demonstrated. Ketotifen also inhibits cAMP phosphodiesterase. Properties of ketotifen which may contribute to its antiallergic activity and its ability to affect the underlying pathology of asthma include inhibition of the development of airway hyper-reactivity associated with activation of platelets by PAF (Platelet Activating Factor), inhibition of PAF-induced accumulation of eosinophils and platelets in the airways, suppression of the priming of eosinophils by human recombinant cytokines and antagonism of bronchoconstriction due to leukotrienes. Ketotifen inhibits of the release of allergic mediators such as histamine, leukotrienes C4 and D4(SRS-A) and PAF.
Additional Information of Ketotifen Tablet
| Pharmacology Class: | Antihistamines For Systemic Use |
| Therapeutic Class: | Antihistamines For Systemic Use |
| Chemical Class: | Other Antihistamines For Systemic Use |
| Synonyms: | Ketotifene | Ketotifeno | Ketotifenum |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Ketotifen Tablet As an oral solid preparation not exceeding 2mg
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.